teixobactin: isolated from an Aquabacteria soil bacterium [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
teixobactin : A cyclodepsipeptide that is isolated from the previously unculturable bacterial species Eleftheria terrae and is active against gram-positive bacteria. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 86341926 |
| CHEMBL ID | 3977597 |
| CHEBI ID | 84192 |
| SCHEMBL ID | 15790568 |
| MeSH ID | M000601847 |
| Synonym |
|---|
| l-serinamide, n-methyl-d-phenylalanyl-l-isoleucyl-l-seryl-d-glutaminyl-d-alloisoleucyl-l-isoleucyl-n-((3s,6s,9s,12r,13s)-6-(((4s)-2-imino-4-imidazolidinyl)methyl)-9,13-dimethyl-3-((1s)-1-methylpropyl) -2,5,8,11-tetraoxo-1-oxa-4,7,10-triazacyclotridec-12-y |
| teixobactin |
| unii-lc730gue72 |
| 1613225-53-8 |
| lc730gue72 , |
| n-methyl-d-phenylalanyl-l-isoleucyl-l-seryl-d-glutaminyl-d-alloisoleucyl-l-isoleucyl-n-{(3s,6s,9s,12r,13s)-6-{[(4s)-2-amino-4,5-dihydro-1h-imidazol-4-yl]methyl}-3-[(2s)-butan-2-yl]-9,13-dimethyl-2,5,8,11-tetraoxo-1-oxa-4,7,10-triazacyclotridecan-12-yl}-l- |
| CHEBI:84192 |
| SCHEMBL15790568 |
| CHEMBL3977597 |
| teixobactin [mi] |
| us9402878, ii |
| bdbm237161 |
| n-[n-methyl-d-phe-ile-ser-d-gln-d-aile-ile-ser-]cyclo[d-thr*-ala-[3-(2-iminoimidazolidine-4beta-yl)-ala-]-ile-] |
| Q18720369 |
| gtpl10972 |
| compound of formula ii [wo2014089053a1] |
| EX-A5149 |
| CS-0022114 |
| HY-P0230 |
Teixobactin is a cyclic undecadepsipeptide that has shown excellent potency against multidrug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) It is a recently discovered "resistance-proof" antimicrobial peptide that targets the bacterial cell wall precursor lipid II.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Teixobactin is a promising new antibiotic that kills a spectrum of Gram-positive pathogens that are considered to be urgent threats by the CDC and the WHO. " | ( Synthesis and application of fluorescent teixobactin analogs. Jones, CR; Morris, MA; Nowick, JS, 2022) | 2.43 |
| "Teixobactin is a cyclic undecadepsipeptide that has shown excellent potency against multidrug-resistant pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). " | ( Development of teixobactin analogues containing hydrophobic, non-proteogenic amino acids that are highly potent against multidrug-resistant bacteria and biofilms. Breukink, E; Goh, ETL; Iyer, A; Lakshminarayanan, R; Madder, A; Newire, E; Parmar, A; Prior, SH; Robertson, MC; Singh, I; To, TY; Yam, JKH; Yang, L, 2023) | 2.71 |
| "Teixobactin is a recently discovered "resistance-proof" antimicrobial peptide that targets the bacterial cell wall precursor lipid II." | ( Dissecting the Binding Interactions of Teixobactin with the Bacterial Cell-Wall Precursor Lipid II. Alexander, FM; Antwi, I; Carney, DW; Chiorean, S; Cochrane, SA; Giltrap, AM; Henninot, A; Kotsogianni, I; Martin, NI; Payne, RJ; Vederas, JC, 2020) | 1.55 |
| "Teixobactin is an unusual depsipeptide natural product that was recently discovered from a previously unculturable soil bacterium and found to possess potent antibacterial activity against several Gram positive pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci." | ( Synthesis and structure-activity relationships of teixobactin. Chen, F; Giltrap, AM; Hoyer, D; Hussein, M; Kang, Z; Karas, JA; Li, J; Payne, RJ; Schneider-Futschik, EK; Swarbrick, J; Velkov, T, 2020) | 1.53 |
| "Teixobactin is a recently discovered promising antibiotic that is claimed to "kill pathogens without detectable resistance" (L." | ( Goddard, MR; Lloyd, DG; Schofield, BJ; Taylor, EJ, 2020) | 1.28 |
| "Teixobactin is a cell wall inhibiting peptide antibiotic, while darobactin inhibits a chaperone and translocator for outer membrane proteins." | ( Spotlight on the Selected New Antimicrobial Innate Immune Peptides Discovered During 2015-2019. Dang, X; Wang, G, 2020) | 1.28 |
| "Teixobactin is a head to side chain cyclodepsipeptide that contains two positive charges. " | ( Converting Teixobactin into a Cationic Antimicrobial Peptide (AMP). Abdel Monaim, SAH; Albericio, F; de la Torre, BG; El-Faham, A; Ramchuran, EJ, 2017) | 2.29 |
| "Teixobactin is a recently described antimicrobial peptide that shows high activity against gram-positive bacteria as well as " | ( Investigation of the N-Terminus Amino Function of Arg Albericio, F; El-Faham, A; Monaim, SAHA; Noki, S; Ramchuran, EJ; Torre, BG, 2017) | 1.9 |
| "Teixobactin is a structurally and mechanistically novel antimicrobial peptide with potent activities against Gram-positive pathogens. " | ( Synthesis and antibacterial studies of teixobactin analogues with non-isostere substitution of enduracididine. Chen, S; Jin, K; Kong, WY; Lam, HY; Li, X; Lo, CH; Lo, CW; Po, KHL; Reuven, JA; Sirinimal, A, 2018) | 2.19 |
| "Teixobactin is a recently described antibiotic of a new class produced by a hitherto undescribed soil microorganism (provisionally named Eleftheria terrae). " | ( Teixobactin, the first of a new class of antibiotics discovered by iChip technology? Piddock, LJ, 2015) | 3.3 |
| Role | Description |
|---|---|
| antibacterial agent | A substance (or active part thereof) that kills or slows the growth of bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| peptide antibiotic | A chemically diverse class of peptides that exhibit antimicrobial properties. |
| cyclodepsipeptide | A depsipeptide in which the amino and hydroxy carboxylic acid residues are connected in a ring. |
| macrocycle | A cyclic compound containing nine or more atoms as part of the cyclic system. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1692566 | Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC 33591 infected in neutropenic CD1 mouse model of thigh infection assessed as reduction in bacterial colony forming unit in thigh at 2.5 to 5 mg/kg, iv administered as single d | 2020 | Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21 | Teixobactin: A Paving Stone toward a New Class of Antibiotics? |
| AID1692564 | Potency index, ratio of vancomycin PD50 to compound PD50 for antibacterial activity against methicillin resistant Staphylococcus aureus ATCC 33591 infected in iv dosed CD1 mouse model of septicemia assessed as protection against lethal infection administe | 2020 | Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21 | Teixobactin: A Paving Stone toward a New Class of Antibiotics? |
| AID1692539 | Antibacterial activity against methicillin resistant Staphylococcus aureus incubated for 20 hrs by CLSI based broth microdilution method | 2020 | Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21 | Teixobactin: A Paving Stone toward a New Class of Antibiotics? |
| AID1692541 | Antibacterial activity against methicillin sensitive Staphylococcus aureus incubated for 20 hrs by CLSI based broth microdilution method | 2020 | Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21 | Teixobactin: A Paving Stone toward a New Class of Antibiotics? |
| AID1692565 | Antibacterial activity against Streptococcus pneumoniae ATCC 6301 infected in CD1 mouse model of pneumonia assessed as reduction in bacterial colony forming unit in lungs at 0.5 mg/kg, iv administered as single dose starting from 24 to 36 hrs post infecti | 2020 | Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21 | Teixobactin: A Paving Stone toward a New Class of Antibiotics? |
| AID1692540 | Antibacterial activity against methicillin sensitive Staphylococcus aureus incubated for 20 hrs in presence of 10% serum by CLSI based broth microdilution method | 2020 | Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21 | Teixobactin: A Paving Stone toward a New Class of Antibiotics? |
| AID1692563 | Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC 33591 infected in iv dosed CD1 mouse model of septicemia assessed as protection against lethal infection administered as single dose starting from 1 hr post infection and meas | 2020 | Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21 | Teixobactin: A Paving Stone toward a New Class of Antibiotics? |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 49 (80.33) | 24.3611 |
| 2020's | 12 (19.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (48.70) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 11 (18.03%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 50 (81.97%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||